The CYP2D6 VCF Translator

被引：10
|
作者：
Qiao, W. [1 ]
Wang, J. [1 ,2 ]
Pullman, B. S. [3 ]
Chen, R. [1 ,2 ]
Yang, Y. [1 ]
Scott, S. A. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA
[3] Univ Calif San Diego, Dept Comp Sci & Engn, La Jolla, CA 92093 USA
来源：
PHARMACOGENOMICS JOURNAL | 2017年 / 17卷 / 04期
基金：
美国国家卫生研究院;
关键词：
ALLELE NOMENCLATURE; CYTOCHROME-P450; METABOLISM; VARIANTS; DEFECT; GENES; RARE;
D O I：
10.1038/tpj.2016.14
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：301 / 303
页数：3
相关论文
共 50 条
  • [1] The CYP2D6 VCF Translator
    W Qiao
    J Wang
    B S Pullman
    R Chen
    Y Yang
    S A Scott
    [J]. The Pharmacogenomics Journal, 2017, 17 : 301 - 303
  • [2] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [3] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
    Kiss, Adam Ferenc
    Toth, Katalin
    Juhasz, Cintia
    Temesvari, Manna
    Paulik, Jozsef
    Hirka, Gabor
    Monostory, Katalin
    [J]. MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
  • [4] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [5] Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6
    Livezey, Mara R.
    Briggs, Erran D.
    Bolles, Amanda K.
    Nagy, Leslie D.
    Fujiwara, Rina
    Furge, Laura Lowe
    [J]. XENOBIOTICA, 2014, 44 (04) : 309 - 319
  • [6] Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR
    Hersberger, M
    Marti-Jaun, J
    Rentsch, K
    Hänseler, E
    [J]. CLINICAL CHEMISTRY, 2000, 46 (08) : 1072 - 1077
  • [7] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    Gressier, F.
    Verstuyft, C.
    Hardy, P.
    Becquemont, L.
    Corruble, E.
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
  • [8] CYP2D6 genotypes in a Japanese population:: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10
    Nishida, Y
    Fukuda, T
    Yamamoto, I
    Azuma, J
    [J]. PHARMACOGENETICS, 2000, 10 (06): : 567 - 570
  • [9] CYP2D6*36 gene arrangements within the CYP2D6 locus:: Association of CYP2D6*36 with poor metabolizer status
    Gaedigk, A
    Bradford, LD
    Alander, SW
    Leeder, JS
    [J]. DRUG METABOLISM AND DISPOSITION, 2006, 34 (04) : 563 - 569
  • [10] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    F. Gressier
    C. Verstuyft
    P. Hardy
    L. Becquemont
    E. Corruble
    [J]. Journal of Neural Transmission, 2015, 122 : 35 - 42
12345